Study included more than 1000 chemonaïve patients

Stratified by histology and age1,2

stratified-histologies

ABRAXANE 100 mg/m2 weekly + carboplatin arm (n=521)

Three-quarters of the patients had a history of smoking1a

aThe smoking status was unknown for 2 patients in the ABRAXANE + carboplatin arm (n=519).1a

Study included more than 1000 chemonaïve patients

Stratified by histology and age1,2

stratified-histologies
ABRAXANE 100 mg/m2 weekly + carboplatin arm (n=521)

Three-quarters of the patients had a history of smoking1a

aThe smoking status was unknown for 2 patients in the ABRAXANE + carboplatin arm (n=519).1a

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.